Clinical Trials

Mateon announced that from its first schedule analysis from ongoing phase 2/3 Study(FOCUS) in patients with Platinum-resistant Ovarian Cancer result Positive. The analysis was…
Read More...

Prometic Life Sciences announced that it has received approval from FDA on the design of the first of its PBI-4050 planned phase 2/3 clinical trials for IPF based on the efficacy data…
Read More...

RXi Pharmaceuticals announced that Gerrit Dispersyn, Dr. Med Sc. has been appointed as RXi's Chief Development Officer effective April 24, 2017. RXi's current Chief Development…
Read More...

Allergan announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan's cenicriviroc (CVC) and Novartis' lead FXR agonist for…
Read More...

Immune Therapeutics a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal, its proprietary formulation of lower-dose naltrexone,…
Read More...

Biocryst announced that it has received approvals from Europe's initial regulatory to explore a new Oral liquid formulation of BCX7353 for the treatment of Acute attacks in patients…
Read More...

Novartis announced that it has it has it has exercised an option to in-license ECF843 for ophthalmic indication worldwide to strengthen R&D pipeline. The closing of the deal is…
Read More...

GE Healthcare and CBMG (Cellular Biomedicine Group) collaborated to co-develop certain industrial control processes in CAR-T (Chimeric Antigen Receptor T-cell) and stem-cell…
Read More...

Nuvox Pharma announces that the FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with…
Read More...

Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics announced…
Read More...

Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies announces that the first patient with soft tissue sarcoma (STS) has been treated in the Phase 2…
Read More...

Neurocrine Biosciences’ Ingrezza (valbenazine) capsules has been approved by US FDA (food and Drug Administration) for treatment of tardive dyskinesia (TD). TD is characterised by…
Read More...

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel…
Read More...

Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell…
Read More...

Medidata and clinical-stage pharmaceutical company Karyopharm Therapeutics announced an expanded partnership to bring novel machine-learning technology and targeted risk-based…
Read More...

uniQure announced the online publication in Gene Therapy of data demonstrating widespread transduction in the CNS following direct injection of uniQure's AAV5 vector in a large animal…
Read More...

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it…
Read More...

Allergan plc, a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative…
Read More...

Intec Pharma Ltd., a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a…
Read More...

Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a…
Read More...